Novartis, CH0012005267

Novartis stock: Morgan Stanley sets USD 156.00 target for Novartis stock

Published on 10/20/2026 at 15:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales rose 3.00 percent to USD 14.41 billion in the quarter. Novartis stock costs EUR 135.78 on October 20, 2026, up 1.81 percent versus Xetra close.

Analyst target and financial dates

Morgan Stanley set a USD 156.00 target on October 6, 2026.
Novartis reported USD 14.41 billion in second-quarter sales, up 3.00 percent year over year.
Novartis stock costs EUR 135.78 at Lang & Schwarz on October 20, 2026 at 3:10 p.m. CEST, 1.81 percent above the Xetra close of October 19, 2026.
Novartis has scheduled third-quarter results for October 27, 2026.

Extreme Nahaufnahme einer weißen Tablette mit Bruchkerbe und feiner granularer Textur — Novartis AG CH0012005267 – Extreme Makroaufnahme einer weißen Tablette mit Bruchkerbe und feiner Oberflächentextur, Illustration mit AI erstellt.

Novartis AG (CH0012005267) is trading against a USD 156.00 Morgan Stanley target set on October 6, 2026, with the target 3.86 percent above the USD 150.20 price on October 19. MarketBeat reported that Morgan Stanley maintained an overweight rating and set the target. Novartis stock was trading at EUR 135.78 at Lang & Schwarz on October 20, 2026 at 3:10 p.m. CEST, up 1.81 percent versus the Xetra close of October 19, 2026 at EUR 133.36.

Second-quarter sales set the base

Novartis reported USD 14.41 billion in second-quarter net sales, up 3.00 percent in US dollars from USD 14.05 billion a year earlier. Core operating income was USD 5.94 billion, with a 41.20 percent margin, compared with 42.20 percent in the prior-year quarter. Ticker Scout reported the figures from Novartis' second-quarter 2026 filing.

The same report listed core earnings per share of USD 2.41 for the quarter and free cash flow of USD 5.56 billion, down 12.00 percent year over year. Those figures give the coming report a defined comparison base rather than a standalone sales number.

Stock position and valuation

On the Swiss Exchange, Novartis was quoted at CHF 124.20 on October 20, 2026 at 3:31 p.m. CET. The same quote page listed a CHF 97.05 to CHF 132.68 52-week range, a CHF 246.43 billion market capitalization, and a 2.93 percent dividend yield.

The euro quotation sits 1.81 percent above the Xetra close, while the latest Swiss quotation was down 0.40 percent on its own exchange. The separate venue readings should not be combined into one daily move.

What comes next for Novartis?

Novartis has scheduled third-quarter and nine-month 2026 results for October 27, 2026, with the webcast set for 1:00 p.m. CET. The investor-relations calendar also lists a Remibrutinib in multiple sclerosis investor call for October 23, 2026. Novartis lists both dates on its investor page.

For the third quarter, the published consensus is USD 14.56 billion in revenue and USD 2.25 in earnings per share, versus USD 14.36 billion and USD 2.25 in the prior-year quarter. MarketBeat gives the estimates and the October 27, 2026 reporting date.

Investor view before results

The immediate test is whether quarterly sales can meet the USD 14.56 billion estimate while profitability holds near the 41.20 percent core operating margin. The USD 156.00 Morgan Stanley target provides a separate valuation marker, but the next company-specific catalyst is the October 27 report.

The further course of trading is shown by the continuously updated real-time quote of Novartis stock.